Literature DB >> 16105756

Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita: report of a case.

Patrizia Comoli1, Sabrina Basso, Guan-Cheng Huanga.   

Abstract

Dyskeratosis congenita (DC) is a very rare inherited disorder characterized by skin pigmentation, nail dystrophy, and mucosal leukoplakia. It is also associated with a variety of noncutaneous abnormalities, such as fatal pulmonary complications, malignancy, and bone marrow failure. We report the case of a 32-year-old man with DC associated with severe aplastic anemia (SAA). The traditional treatment of DC-associated SAA is allogeneic hematopoietic stem cell transplantation (HSCT). However, in this case, an HLA-matched donor was not available. Therefore our patient was given intensive immunosuppressive therapy with antilymphocyte globulin (ALG) and cyclosporine A (CsA). The hemogram findings improved after the treatment, but the patient died of pulmonary complications after being in stable condition for 6 months. The results support the possible use of intensive immunosuppression with ALG and CsA for DC-associated SAA as an alternative treatment for patients who are not eligible for HSCT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16105756     DOI: 10.1532/IJH97.A10416

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  11 in total

Review 1.  Dyskeratosis congenita in all its forms.

Authors:  I Dokal
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

2.  Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO).

Authors:  A Bacigalupo; B Bruno; P Saracco; E Di Bona; A Locasciulli; F Locatelli; A Gabbas; C Dufour; W Arcese; G Testi; G Broccia; M Carotenuto; P Coser; T Barbui; P Leoni; A Ferster
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

3.  1.4 Mb candidate gene region for X linked dyskeratosis congenita defined by combined haplotype and X chromosome inactivation analysis.

Authors:  S W Knight; T J Vulliamy; N S Heiss; G Matthijs; K Devriendt; J M Connor; M D'Urso; A Poustka; P J Mason; I Dokal
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

4.  Immunostimulatory effects of different antilymphocyte globulin preparations: a possible clue to their clinical effect.

Authors:  Y Kawano; C Nissen; A Gratwohl; B Speck
Journal:  Br J Haematol       Date:  1988-01       Impact factor: 6.998

5.  Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation.

Authors:  M Yabe; H Yabe; K Hattori; T Morimoto; T Hinohara; I Takakura; T Shimizu; K Shimamura; X Tang; S Kato
Journal:  Bone Marrow Transplant       Date:  1997-02       Impact factor: 5.483

6.  Dyskeratosis congenita with isolated neutropenia and granulocyte colony-stimulating factor treatment.

Authors:  Kutluhan Yilmaz; H Serhat Inalöz; Bünyamin Unal; Elif Güler
Journal:  Int J Dermatol       Date:  2002-03       Impact factor: 2.736

7.  Unusual complications after bone marrow transplantation for dyskeratosis congenita.

Authors:  V Rocha; A Devergie; G Socié; P Ribaud; H Espérou; N Parquet; E Gluckman
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

8.  Dyskeratosis Congenita (DC) Registry: identification of new features of DC.

Authors:  S Knight; T Vulliamy; A Copplestone; E Gluckman; P Mason; I Dokal
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

9.  Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party.

Authors:  A Bacigalupo; G Broccia; G Corda; W Arcese; M Carotenuto; A Gallamini; F Locatelli; P G Mori; P Saracco; G Todeschini
Journal:  Blood       Date:  1995-03-01       Impact factor: 22.113

10.  Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita.

Authors:  A A Langston; J E Sanders; H J Deeg; S W Crawford; C Anasetti; K M Sullivan; M E Flowers; R Storb
Journal:  Br J Haematol       Date:  1996-03       Impact factor: 6.998

View more
  2 in total

1.  Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita.

Authors:  Mohamad M Al-Rahawan; Neelam Giri; Blanche P Alter
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

Review 2.  Molecular insight of dyskeratosis congenita: Defects in telomere length homeostasis.

Authors:  Saeed Dorgaleleh; Karim Naghipoor; Zahra Hajimohammadi; Farzad Dastaviz; Morteza Oladnabi
Journal:  J Clin Transl Res       Date:  2022-01-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.